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Collagen degradation fragmentActivation of inﬂammatory reactions by the immune system is of
vital importance to the preservation of cellular and organ integrity in a
hostile environment. It is a complex and ﬁne-tunedmechanism. Insufﬁ-
cient response may cause immunodeﬁciency resulting in infection and
cancer while overactivity may result in diseases like arthritis, diabetes,
atherosclerosis, ischemic heart disease, heart failure, stroke, inﬂamma-
tory bowel disease or Alzheimer's disease.
The inﬂammatory process is activated by different, not yet
completely understood mechanisms, but factors such as age, race, gen-
der, genetics, hypoxia, and antigens are involved. Stimulation of mono-
cytes, macrophages, ﬁbroblasts, and T-cells release numerous cytokines.
Important are TNF-α and interleukin-1, whichmay activate severalme-
talloproteinases (MMPs). Twenty-ﬁve MMPs have been deﬁned; with
speciﬁc proteolytic effects on extracellular matrix (ECM) collagen. To-
gether with their endogenous tissue inhibitors (TIMP) they regulate
the extracellular matrix (ECM).
In patients with rheumatoid arthritis, autoimmune stimulation of
osteoclasts and chondrocytes activate MMPs, which target bone and
cartilage destruction. In the heart, local MMPs stimulate the ECMdegra-
dationwith breakdownof the collagen and elastin framework. Clinically
the atherosclerotic plaque becomes unstable and with ventricular dila-
tation, rupture, and hypertrophy. In addition to local cellular effects,
the hormonal and autonomic system interactwith the inﬂammatory re-
sponse and there is a spillover of inﬂammatory signal molecules to the
systemic circulation with generalized effects.
Patientswith rheumatoid arthritis have elevated levels of circulating
cytokines that may affect other organs besides the joints (Avin-Zubieta
et al., 2012). The additive effects of inﬂammatory expressions in two or
more organ systems raise interesting possibilities regarding pathophys-
iology and treatment targets. People with rheumatoid arthritis have upDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.017.
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the general population, which is not explained by traditional cardiovas-
cular risk factors (Crowson et al., 2013; Midtbø et al., 2014). Antigen in-
duced arthritis in experimental rats activates proteolytic MMPs which
release degradation product of different types of collagen (Siebuhr
et al., 2012). Little is known of a common pathway that also may acti-
vate collagen degradation in other tissues. Degradation products of
more than 20 different collagenmolecules, neo-epitopes, have been de-
scribed. In the present issue of the journal, Dragsbæk and co-workers
(Dragsbæk et al., 2015) examined prospectively the long-time effects
of disturbed homeostasis of ECM. The authors identiﬁed a type 1 colla-
gen degradation fragment (C1M) among 5855 postmenopausal
women and demonstrated that elevated levels (upper compared to
the lowest quartile)were associatedwith 59% increase inmortality dur-
ing an average of 9 year follow-up. The mortality curves diverged up to
9 years. Because C1M was obtained only at baseline, information be-
yond 9 years was confounded. When individuals in the high-risk
group with elevated C1M die, the two curves will eventually converge.
Although the number of events was too small to analyze cause-
speciﬁc events, except cancer and cardiovascular deaths, directional
changes were similar for other events. The results therefore suggest
that disturbed balance in the homeostasis of type 1 collagen is a general
risk factor. The etiology is unknown. It is unclear if the elevated C1M in
postmenopausal women represent a cause or an effect relationship to
mortality. The inclusion of the women is vaguely described “as done
by invitation ensuring no overrepresentation of subjects with a history
of speciﬁc diseases”. However, a history of hypertension, cancer, diabe-
tes and underweight was clearly overrepresented among those who
died (Dragsbæk et al., 2015). These are risk factors, which all cause a
low-grade inﬂammatory activation. In addition, missing information
on the occurrence of rheumatic arthritis and other autoimmune inﬂam-
matory diseases make it difﬁcult to conclude about the mechanisms
that contributed to the deregulated ECM.
SeveralMMPsmay be responsible for the neo-epitope C1M from col-
lagen type 1. In particular, MMP-2 and -9 are elevated acutely in infarct-
ed tissue and are important for the tissue repair. However, elevated
levels are also associated with increased incidence of cardiac rupture
and portends a poor prognosis. MMP2 is closely related to left ventricu-
lar remodeling and to changes in proBNP. Lowering of MMP2 may pre-
dict reverse remodeling with high sensitivity and speciﬁcity (Morishita
et al., 2015). Unfortunately, MMPs were not examined in the present
study so which MMP was involved in these presumed healthy women
remains unclear. Degradation of other collagens results in speciﬁc
neo-epitopes. Cathepsin K is another speciﬁc proteasewith ability to ca-
tabolize elastin, collagen, and gelatin in bone and cartilage with releasethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ed CTX-1 and all-cause mortality in the present cohort. Underscoring
the speciﬁcity of the MMP-collagen type 1 relationship as a risk factor
(Dragsbæk et al., 2015).
Local activation of MMPs is also closely associated with progression
of cancer although the decisive mechanism is unknown (Bauvois,
1825). However, it may explain the association between C1M and
death from cancer (Dragsbæk et al., 2015).
Other protein molecules released from collagen like biglycan and
mimecan are elevated in heart failure patients and have been shown
to be associated with adverse outcome. They added, however, no
extra information beyond conventional risk factors, when N terminal
pro-BNP was included (Ueland et al., 2015). Dragsbæk and coworkers
did not account for ProBNP, which weakens the claim that C1M was
an independent risk factor.
The clinical implications of activated collagen degradation are un-
clear. MMP/TIMP system is important in tissue healing and repair as
well as in tissue remodeling and disease progression. Patients with au-
toimmune diseases like rheumatic arthritis and inﬂammatory bowel
disease beneﬁt from treatments targeting molecules directly involved
in the degradation of collagen. The data also suggest that inhibitors of
inﬂammation attenuate the excess risk for heart failure development.
However, these results contrast the disappointing results of randomized
clinical trials in patients with established heart failure, NYHA class II–IV.
TNF-α inhibitors in 3 trials resulted in no or increased number of deaths
and hospitalization for heart failure (Anker and Coats, 2002; Chung
et al., 2003). On the other hand, experiments in a ratmodel of heart fail-
ure demonstrated thatMMP activity contributed to LV dilation and pro-
gression to LV dysfunction. Speciﬁc inhibitors ofMMPs, includingMMP-
2 attenuated left ventricular dilatation and dysfunction. Unfortunately,
prolonged exposure to MMP inhibitors stimulates a pro-ﬁbrotic re-
sponse and scar formation. This may convert systolic dysfunction into
a diastolic dysfunction. Furthermore, ﬁbromyalgia is a limiting side ef-
fect for the clinical use of MMP inhibitors.
It is interesting that angiotensin-converting enzyme may activate
MMP and that part of the favorable effect of an ACE inhibitor in heart
failure is reducing the MMP activity.
– The study by Dragsbæk and coworkers suggests that increased turn-
over of collagen type-1 is a general risk factor for all-causemortality.
– The role of C1M as a ubiquitous riskmarker of death is intriguing but
needs to be conﬁrmed.– Inﬂammatory pathways may be additive and explain the excess
mortality of ischemic heart disease in patients with autoimmune
diseases.
– However, the response to anti-inﬂammatory treatment remains dif-
ferent for autoimmune disorders, cancer, and heart failure and sug-
gests different speciﬁcity for treatment modalities.
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